← back to search

Kristian Unger

German Cancer Research Center · DE
Area of research
Cancer Research · Otorhinolaryngology
Research interest
Research interests include Head and Neck Cancer Studies, MicroRNA in disease regulation, Cancer-related molecular mechanisms research, and Cancer Genomics and Diagnostics.
h-index
44
citations
8,740
works
288
NIH funding
primary concept
Medicine
email

Recent publications

Activated ATF6α is a hepatic tumour driver restricting immunosurveillance
Nature 2026cited by 3position: middledoi
EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer
Molecular Cancer 2025cited by 16position: middledoi
A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development
Nature Communications 2025cited by 9position: middledoi
Targeting VEGF‐A in an Immunocompetent Orthotopic Mouse Model of Mesenchymal Glioblastoma Improves Antitumorigenicity and Decreases Proinflammatory Response in Normal Brain Tissue after Fractionated Radiotherapy
Advanced Therapeutics 2025cited by 0position: contributordoi
ChatGPT's Gastrointestinal Tumor Board Tango: A limping dance partner?
European Journal of Cancer 2024cited by 24position: middledoi
HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx
JHEP Reports 2024cited by 19position: middledoi
ChatGPT's Gastrointestinal Tumor Board Tango: A limping dance partner?
2024cited by 18position: contributordoi
Adjuvant (chemo)radiotherapy for patients with head and neck cancer: can comorbidity risk scores predict outcome?
Strahlentherapie und Onkologie 2024cited by 3position: middledoi
Metabolomic Analysis of Human Cirrhosis and Hepatocellular Carcinoma: A Pilot Study.
2024cited by 2position: contributordoi
Metabolic pathway-based subtypes associate glycan biosynthesis and treatment response in head and neck cancer
npj Precision Oncology 2024cited by 1position: middledoi
Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12).
2024cited by 1position: contributordoi
Sublethal necroptosis signaling promotes inflammation and liver cancer
Immunity 2023cited by 131position: middledoi
Sublethal necroptosis signaling promotes inflammation and liver cancer.
2023cited by 111position: contributordoi
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling
Journal of Hepatology 2023cited by 91position: middledoi
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
2023cited by 79position: contributordoi
Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data
Radiation Oncology 2023cited by 13position: middledoi
Comparative computational analysis to distinguish mesenchymal stem cells from fibroblasts.
2023cited by 12position: contributordoi
Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data.
2023cited by 6position: contributordoi
Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12)
Clinical and Translational Radiation Oncology 2023cited by 5position: middledoi
A Novel Subgroup of UCHL1-Related Cancers Is Associated with Genomic Instability and Sensitivity to DNA-Damaging Treatment
Cancers 2023cited by 3position: middledoi
A Novel Subgroup of UCHL1-Related Cancers Is Associated with Genomic Instability and Sensitivity to DNA-Damaging Treatment.
2023cited by 3position: contributordoi
DNA-methylation and genomic copy number in primary tumors and corresponding lymph node metastases in prostate cancer from patients with low and high Gleason score
Clinical and Translational Radiation Oncology 2023cited by 2position: firstdoi
Mcl-1 deficiency in murine livers leads to nuclear polyploidisation and mitotic errors: Implications for hepatocellular carcinoma
JHEP Reports 2023cited by 2position: contributordoi
DNA-methylation and genomic copy number in primary tumors and corresponding lymph node metastases in prostate cancer from patients with low and high Gleason score.
2023cited by 1position: contributordoi
A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer.
2022cited by 71position: contributordoi
Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD
Developmental Cell 2022cited by 64position: middledoi
Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD.
2022cited by 53position: contributordoi
APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases.
2022cited by 49position: contributordoi
Machine Learning Classifies Ferroptosis and Apoptosis Cell Death Modalities with TfR1 Immunostaining.
2022cited by 40position: contributordoi
Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer.
2022cited by 22position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Claus Belka · Cancer Research Center16 papers (2016–2025)Maximilian Niyazi · Cancer Research Center15 papers (2016–2025)Axel Walch · University of Alaska Anchorage11 papers (2019–2022)Julia Heß · Helmholtz Zentrum München11 papers (2020–2024)Horst Zitzelsberger · Helmholtz Zentrum München9 papers (2016–2024)Kirsten Lauber · German Cancer Research Center9 papers (2016–2023)Mathias Heikenwälder · German Cancer Research Center9 papers (2015–2024)Michael Orth · Deutschen Konsortium für Translationale Krebsforschung5 papers (2021–2025)Michael Orth · LMU Klinikum5 papers (2017–2023)Achim Weber · University of Zurich4 papers (2015–2019)Tobias Riedl · Goethe University Frankfurt4 papers (2020–2024)Daniel F. Fleischmann · German Cancer Research Center4 papers (2020–2023)Roland Rad · Molecular Oncology (United States)4 papers (2019–2024)Julia Hess · Springer Nature4 papers (2019–2023)Horst Zitzelsberger · Deutschen Konsortium für Translationale Krebsforschung4 papers (2021–2025)Kirsten Lauber · University of Tübingen4 papers (2021–2025)Ute Ganswindt · Innsbruck Medical University3 papers (2016–2023)Philipp Baumeister · Ludwig-Maximilians-Universität München3 papers (2022–2024)Frederick Klauschen · Institute of Clinical Cancer Research3 papers (2022–2023)Christian G. Stief · München Klinik3 papers (2020–2023)